Arbutus Biopharma Corp

Company Profile

Arbutus Biopharma Corp had its IPO on 2015-08-03 under the ticker symbol ABUS.

The company operates in the Healthcare sector and Biotechnology industry. Arbutus Biopharma Corp has a staff strength of 0 employees.

Stock update

Shares of Arbutus Biopharma Corp opened at $2.19 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.02 - $2.19, and closed at $2.03.

This is a -7.73% slip from the previous day's closing price.

A total volume of 774,180 shares were traded at the close of the day’s session.

In the last one week, shares of Arbutus Biopharma Corp have slipped by -0.98%.

Arbutus Biopharma Corp's Key Ratios

Arbutus Biopharma Corp has a market cap of $476.33 million, indicating a price to book ratio of 2.8064 and a price to sales ratio of 11.6763.

In the last 12-months Arbutus Biopharma Corp’s revenue was $39.02 million with a gross profit of $-45389000 and an EBITDA of $-61796000. The EBITDA ratio measures Arbutus Biopharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Arbutus Biopharma Corp’s operating margin was -162.03% while its return on assets stood at -19.76% with a return of equity of -45.35%.

In Q4, Arbutus Biopharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 94.8%.

Arbutus Biopharma Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arbutus Biopharma Corp’s profitability.

Arbutus Biopharma Corp stock is trading at a EV to sales ratio of 7.6703 and a EV to EBITDA ratio of -4.5333. Its price to sales ratio in the trailing 12-months stood at 11.6763.

Arbutus Biopharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$195.42 million

Total Liabilities

$32.86 million

Operating Cash Flow

$12.68 million

Capital Expenditure

$59000

Dividend Payout Ratio

0%

Arbutus Biopharma Corp ended 2024 with $195.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $195.42 million while shareholder equity stood at $136.85 million.

Arbutus Biopharma Corp ended 2024 with $0 in deferred long-term liabilities, $32.86 million in other current liabilities, 1318737000.00 in common stock, $-1203803000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.78 million and cash and short-term investments were $146.91 million. The company’s total short-term debt was $372,000 while long-term debt stood at $0.

Arbutus Biopharma Corp’s total current assets stands at $151.14 million while long-term investments were $37.36 million and short-term investments were $116.14 million. Its net receivables were $4.23 million compared to accounts payable of $16.03 million and inventory worth $0.

In 2024, Arbutus Biopharma Corp's operating cash flow was $12.68 million while its capital expenditure stood at $59000.

Comparatively, Arbutus Biopharma Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$2.03

52-Week High

$3.22

52-Week Low

$1.85

Analyst Target Price

$5.4

Arbutus Biopharma Corp stock is currently trading at $2.03 per share. It touched a 52-week high of $3.22 and a 52-week low of $3.22. Analysts tracking the stock have a 12-month average target price of $5.4.

Its 50-day moving average was $2.12 and 200-day moving average was $2.54 The short ratio stood at 6.54 indicating a short percent outstanding of 0%.

Around 2565.7% of the company’s stock are held by insiders while 3331.4% are held by institutions.